Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
09 Ottobre 2023 - 1:00PM
Business Wire
Almost 1 in 2 people with diabetes using a
short-term CGM are not fully satisfied with their current
systemi
Ascensia Diabetes Care, a global diabetes care company, and
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) systems
for people with diabetes, have launched a new U.S. advertising and
marketing campaign for Eversense® E3 CGM System. ‘The CGM for Real
Life’ campaign is designed to significantly drive awareness of
Eversense E3 as a unique CGM option that is ideally suited to
supporting the everyday lives of people with diabetes. A sample of
the new advertising assets can be found here.
For the 37 million people living with diabetes in the U.S.ii,
CGM has become an indispensable tool in managing the condition.
However, it’s estimated almost half of the people using the two
mostly commonly known CGM brands are not fully satisfied with their
current systemi. Many people with diabetes take long-term breaks
from their CGMs, either because of sensors falling off before
expected wear duration or because they don’t want to have something
attached to their bodyi. Eversense E3 is the longest lasting CGM
available, with 6-month sensor wear duration and two sensor
insertion and removal procedures per year. ‘The CGM for Real Life’
campaign aims to highlight the reality of the diabetes experience,
through the everyday complexities, successes, and challenges that
people with diabetes face. The campaign demonstrates how Eversense
E3 provides a differentiated CGM option, with unparalleled
flexibility and long-term use that allows it to seamlessly
integrate into real life.
“This campaign is designed to challenge the status quo in
continuous glucose monitoring, which for too long has meant
self-insertion and sensors that can either disrupt activities or
fall off,” said Rudy Thoms, VP, CGM Commercial U.S. of Ascensia
Diabetes Care. “We know that Eversense has the potential to be
game-changing for people with diabetes, and so the opportunity to
bring it to the attention of more people than ever before is really
exciting.”
“CGMs are often portrayed as one size fits all, but managing
diabetes is complex and everyone is different. What works for one
person may not work for the next and I personally had a real
struggle with short-term CGMs,” said Chris Ruden, Keynote Speaker
and Eversense Brand Ambassador. “Eversense fits seamlessly into my
life and once it’s inserted, I can forget about the hassle of
replacements for 6 months. I have a busy life and I don’t want
diabetes to get in my way. Thankfully, with Eversense it
doesn’t.”
‘The CGM for Real Life’ campaign is a coordinated awareness
effort delivering information about Eversense E3 directly to U.S.
consumers. It is the first time that the brand is launching a
campaign across connected TV and linear TV in five states, in
addition to digital and social, with the aim to raise awareness of
the product’s unique benefits among people with diabetes and
healthcare professionals. Senseonics and Ascensia provided an
overview of the campaign in a webcast to investors on September 21,
2023. A replay of the webcast is available on the Senseonics
website at
www.senseonics.com/investor-relations/events-and-publications/events-and-presentations
(Gilmartin Group Emerging Growth Showcase).
Designed by Senseonics and brought to patients by Ascensia, the
Eversense E3 CGM System offers people with diabetes:
- The longest lasting CGM available, with 6-month sensor wear
duration and two sensor insertion and removal procedures per
year
- Exceptional accuracyiii, with a mean absolute relative
difference (MARD) of 8.5%iv demonstrated in the PROMISE Study for
the duration of sensor wear
- The only CGM with a removable transmitter which can be taken on
and off without wasting a sensor or adding a warm up periodv
- The only CGM with predictive on-body alerts to never miss a
critical event, especially at night while sleeping or when away
from your phone
Potential Eversense E3 users can go to www.eversensecgm.com to
learn more. Physicians, nurse practitioners and physician
assistants who are interested in offering the Eversense E3 CGM
System can sign up at www.bit.ly/eversense-become-provider.
Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more
about the first and only long-term implantable CGM system. For
important safety information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523)
company.
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on
helping people with diabetes. Our mission is to empower those
living with diabetes through innovative solutions that simplify and
improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood
glucose monitoring systems and the exclusive global distribution
partner for the Eversense® Continuous Glucose Monitoring Systems
from Senseonics. These products combine advanced technology with
user-friendly functionality to help people with diabetes manage
their condition and make a positive difference to their lives. As a
trusted partner in the diabetes community, we collaborate closely
with healthcare professionals and other partners to ensure our
products meet the highest standards of accuracy, precision and
reliability, and that we conduct our business compliantly and with
integrity.
Ascensia is a member of PHC Group and was established in 2016
through the acquisition of Bayer Diabetes Care by PHC Holdings
Corporation. Ascensia products are sold in more than 100 countries.
Ascensia has around 1,300 employees and operations in 31
countries.
For further information, please visit the Ascensia Diabetes Care
website at: http://www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare
company with a mission of contributing to the health of society
through healthcare solutions that have a positive impact and
improve the lives of people. Its subsidiaries (referred to
collectively as PHC Group) include PHC Corporation, Ascensia
Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation.
Together, these companies develop, manufacture, sell and service
solutions across diabetes management, healthcare solutions, life
sciences and diagnostics. PHC Group’s consolidated net sales in
FY2021 were JPY 356.4 billion with global distribution of products
and services in more than 125 countries. www.phchd.com
About Eversense
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels for up to 180
days in persons with diabetes age 18 and older. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration primarily one time
a day after day 21, and when symptoms do not match CGM information
or when taking medications of the tetracycline class. The sensor
insertion and removal procedures are performed by a health care
provider. The Eversense E3 CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology
company focused on the development and manufacturing of glucose
monitoring products designed to transform lives in the global
diabetes community with differentiated, long-term implantable
glucose management technology. Senseonics' CGM systems, Eversense®,
Eversense® XL and Eversense® E3 include a small sensor inserted
completely under the skin that communicates with a smart
transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
©2023 Ascensia Diabetes Care Holdings AG. All right reserved.
Ascensia, the Ascensia Diabetes Care logo and Contour are
trademarks and/or registered trademarks of Ascensia Diabetes Care
Holdings AG.
i dQ&A Diabetes Connection Patient Panel Report, Q2 2023 ii
American Diabetes Association (ADA). Statistics About Diabetes.
https://diabetes.org/about-us/statistics/about-diabetes iii Garg S.
et al. Evaluation of Accuracy and Safety of the Next-Generation Up
to 180-Day Long-Term Implantable Eversense Continuous Glucose
Monitoring System: The PROMISE Study. Diabetes Technology &
Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182 iv MARD of
9.1% was observed in primary sensor in the PROMISE Study v There is
no glucose data generated when the transmitter is removed
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231009491571/en/
Lorraine Chandler, Lorraine.Chandler@Ascensia.com
Grafico Azioni Senseonics (AMEX:SENS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Senseonics (AMEX:SENS)
Storico
Da Mag 2023 a Mag 2024